Skip to main content
Ocular seeks FDA nod for expanded use of Dextenza
1/11/2019

A supplemental marketing application has been submitted to the FDA by Ocular Therapeutix for the use of Dextenza, or dexamethasone ophthalmic insert, in patients with post-ophthalmic surgery ocular inflammation. The drug was approved to treat ocular pain after ophthalmic surgery.

Full Story: